M Juszczak
Overview
Explore the profile of M Juszczak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown K, Cheng Y, Harley S, Allen C, Claridge M, Adam D, et al.
J Nutr Health Aging
. 2022 Aug;
26(8):792-798.
PMID: 35934824
Objectives: Patients with aortic aneurysms (AA) are often co-morbid and susceptible to frailty. Low core muscle mass has been used as a surrogate marker of sarcopenia and indicator of frailty....
2.
Wierucka-Rybak M, Wolak M, Juszczak M, Drobnik J, Bojanowska E
J Physiol Pharmacol
. 2016 Aug;
67(3):457-63.
PMID: 27512006
Previous studies reported that the co-injection of leptin and cannabinoid CB1 receptor antagonists reduces food intake and body weight in rats, and this effect is more profound than that induced...
3.
Juszczak M, Roszczyk M, Kowalczyk E, Stempniak B
J Physiol Pharmacol
. 2015 Jan;
65(6):777-84.
PMID: 25554981
Melatonin exerts its biological role acting via G protein-coupled membrane receptors - MT1 and MT2, as well as through cytoplasmic and/or nuclear receptors. Melatonin has previously been shown to change...
4.
Juszczak M, Matysiak J, Szeliga M, Pozarowski P, Niewiadomy A, Albrecht J, et al.
Bioorg Med Chem Lett
. 2012 Aug;
22(17):5466-9.
PMID: 22877634
The anticancer potential of 2-amino-1,3,4-thiadiazole compounds has been documented by in vitro and in vivo studies. In our previous research, we described the synthesis as well as the antiproliferative and...
5.
Juszczak M, Steger R, Debeljuk L, Fadden C, Rao J, Borg K, et al.
Endocrine
. 2010 Dec;
4(3):223-31.
PMID: 21153278
The pineal gland has been shown to affect plasma oxytocin (OT) levels, but the mechanism of this action is not apparent. In the present study, the ability of the photoperiod...
6.
Boczek-Leszczyk E, Stempniak B, Juszczak M
J Physiol Pharmacol
. 2010 Sep;
61(4):459-66.
PMID: 20814074
The influence of gonadotrophin-releasing hormone (GnRH) and its analogues (i.e., agonist and antagonist) on vasopressin (VP) release from the rat hypothalamo-neurohypophysial (H-N) system was studied both in vitro and in...
7.
Juszczak M, Boczek-Leszczyk E
J Physiol Pharmacol
. 2008 Oct;
59(3):553-62.
PMID: 18953097
The aim of the present study was to investigate the effect of peptide NK-1 and NK-2 receptors agonists and antagonists (and their natural ligands, i.e., substance P and neurokinin A)...
8.
Juszczak M, Boczek-Leszczyk E, Stempniak B
J Physiol Pharmacol
. 2008 Jan;
58(4):829-43.
PMID: 18195491
The aim of the present study was to investigate the influence of melatonin on vasopressin (AVP) release from the rat hypothalamo-neurohypophysial (H-NH) system, both in vivo and in vitro, possibly...
9.
Juszczak M, Furykiewicz-Nykis K, Stempniak B
J Physiol Pharmacol
. 2004 Dec;
55(4):739-49.
PMID: 15613740
Present investigations were undertaken to study the influence of peptide NK-1 and NK-2 receptor agonists and antagonists as well as substance P and neurokinin A (the natural ligands for these...
10.
Gruson B, Veyssier P, Coquin-Radeau E, Juszczak M, Darnige L
Rev Med Interne
. 2004 Oct;
25(10):769-70.
PMID: 15471608
No abstract available.